Antidrug antibody assay validation: Industry survey results

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 133-138

  Gorovits, Boris ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Antidrug antibody; Antiproduct antibody; Biopharmaceutics; Immunogenicity

Indexed keywords

DRUG; DRUG ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; CONFERENCE PAPER; DRUG INDUSTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; IMMUNOGENICITY; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

ANTIBODIES; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; BINDING, COMPETITIVE; BIOLOGICAL PRODUCTS; CALIBRATION; CHEMILUMINESCENT MEASUREMENTS; DATA COLLECTION; DRUG INDUSTRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LABORATORIES; PHARMACEUTICAL PREPARATIONS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOCIETIES, PHARMACEUTICAL; STATISTICS, NONPARAMETRIC; VALIDATION STUDIES AS TOPIC;

EID: 65549156596     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9091-6     Document Type: Conference Paper

References (18)

1. Proceedings of the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use: Tripartite guideline, S6: Preclinical Safety Evaluation Of Biotechnology-Derived Pharmaceuticals, July 1997
2. Committee for Medicinal Products (CHMP) For Human Use: Concept paper on immunogenicity assessment of therapeutic proteins, February 2006, EMEA/ CHMP/BMWP/246511/2005
3. D. J. Snodin, and P. R. Ryle. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. Biodrugs. 20(1):25-52 (2006).
4. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360 (2002).
5. A. S. Rosenberg, and A. Worobec. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: Considering consequences of the immune response to a protein. BioPharm. Int. 17:22-26 (2004).
6. A. S. Rosenberg, and A. Worobec. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm. Int. 17:34-42 (2004).
7. A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S. J. Swanson, G. Taniguchi, D. Wierda, and L. A. Zuckerman. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 289:1-16 (2004).
8. S. J. Swanson. Characterization of an immune response. Dev. Biol (Basel). 122:95-101 (2005).
9. M. Wadhwa, and R. Thorpe. Strategies and assays for the assessment of unwanted immunogenicity. J. Immunotoxicol. 3(3):115-121 (2006).
10. E. Koren, H. Smith, W. Shores, G. Shankar, D. Finco-Kent, Y.-C. Barett, V. Devanarayan, B. Gorovits, S. Gupta, T. Parish, V. Quarmby, A. Spencer, S. Swanson, G. Taniguchi, L. Zuckerman, and A. Mire-Sluis. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Meth. 33:1-9 (2008).
11. G. Shankar, V. Devanarayan, Y.-C. Barrett, R. Bowsher, D. Finco-Kent, M. Fiscella, B. Gorovits, S. Kirschner, M. Moxness, T. Parish, V. Quarmby, E. Shores, H. Smith, W. Smith, J. Zhong, L. Zuckerman, and E. Koren. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48:1267-1281 (2008).
12. G. Shankar, C. Pendley, and K. E. Stein. A risk-based bioanalytical for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25:555-561 (2007).
13. G. Shankar, E. Shores, C. Wagner, and A. R. Mire-Sluis. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24(6):274-280 (2006).
14. J. A. Lofgren, S. Dhandapani, J. J. Pennucci, C. M. Abbott, D. T. Mytych, A. Kaliyaperumal, S. J. Swanson, and M. C. Mullenixl. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 178:7467-7472 (2007).
15. M. Liang, S. L. Klakamp, C. Funelas, H. Lu, B. Lam, C. Herl, A. Umble, A. W. Drake, P. Min, N. Ageyeva, R. Pasumarthi, and L. K. Roskos. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5:655-662 (2007).
16. J. W. A. Findlay, W. C. Smith, J. W. Lee, G. D. Nordblom, I. Das, B. S. DeSilva, M. N. Khan, and R. R. Bowsher. Validation of Immunoassays for bioanalysis: A pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21:1249-1273 (2000).
17. A. Patton, M. C. Mullenix, S. J. Swanson, and E. Koren. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods. 304:189-195 (2005).
18. J. A. Lofgren, I. Wala, E. Koren, S. J. Swanson, and S. Jing. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods. 308:101-108 (2006).